• Je něco špatně v tomto záznamu ?

The Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis

P. Rajwa, K. Mori, NA. Huebner, DT. Martin, PC. Sprenkle, JC. Weinreb, G. Ploussard, B. Pradere, SF. Shariat, MS. Leapman

. 2021 ; 206 (3) : 507-516. [pub] 20210427

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, metaanalýza, systematický přehled

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025039

PURPOSE: Although the Prostate Imaging-Reporting and Data System™ version 2 (PI-RADS™ v2) is a reliable diagnostic tool for significant prostate cancer, less is known about the prognostic significance of the structured reporting scheme for estimating oncologic outcomes after treatment. We aimed to synthesize the available evidence regarding the association of PI-RADS v2 score and risk of biochemical recurrence (BCR) among patients undergoing primary definitive treatment for prostate cancer. MATERIALS AND METHODS: We systematically queried the PubMed® and Web of Science™ databases to identify studies addressing the association between the PI-RADS v2 and treatment outcomes. We included studies through November 2020 that assessed the independent prognostic significance of PI-RADS v2. After assessing risk of bias and quality, we conducted a formal meta-analysis to estimate the pooled effects of prostate magnetic resonance imaging (MRI) classification on the risk of BCR. RESULTS: We identified 9 and 7 eligible studies including 2,274 and 1,215 patients for the systematic review and meta-analysis, respectively. Eight were conducted in the context of radical prostatectomy and 1 post-radiation. Among patients treated with radical prostatectomy, higher PI-RADS v2 scores were significantly associated with risk of BCR (pooled HR 3.06, 95% CI 2.16-4.33; p <0.01). There was no significant heterogeneity among studies. For all studies, PI-RADS v2 score remained significantly associated with BCR (pooled HR 3.19, 95% CI 2.28-4.45; p <0.01). CONCLUSIONS: Prostate MRI findings assessed with the PI-RADS v2 classification were independently associated with risk of BCR after definitive local therapy, primarily based on data from radical prostatectomy. These findings support the prognostic significance of MRI, in addition to its role in prostate cancer diagnosis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025039
003      
CZ-PrNML
005      
20211026134201.0
007      
ta
008      
211013s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/JU.0000000000001821 $2 doi
035    __
$a (PubMed)33904755
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rajwa, Pawel $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Medical University of Silesia, Zabrze, Poland
245    14
$a The Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis / $c P. Rajwa, K. Mori, NA. Huebner, DT. Martin, PC. Sprenkle, JC. Weinreb, G. Ploussard, B. Pradere, SF. Shariat, MS. Leapman
520    9_
$a PURPOSE: Although the Prostate Imaging-Reporting and Data System™ version 2 (PI-RADS™ v2) is a reliable diagnostic tool for significant prostate cancer, less is known about the prognostic significance of the structured reporting scheme for estimating oncologic outcomes after treatment. We aimed to synthesize the available evidence regarding the association of PI-RADS v2 score and risk of biochemical recurrence (BCR) among patients undergoing primary definitive treatment for prostate cancer. MATERIALS AND METHODS: We systematically queried the PubMed® and Web of Science™ databases to identify studies addressing the association between the PI-RADS v2 and treatment outcomes. We included studies through November 2020 that assessed the independent prognostic significance of PI-RADS v2. After assessing risk of bias and quality, we conducted a formal meta-analysis to estimate the pooled effects of prostate magnetic resonance imaging (MRI) classification on the risk of BCR. RESULTS: We identified 9 and 7 eligible studies including 2,274 and 1,215 patients for the systematic review and meta-analysis, respectively. Eight were conducted in the context of radical prostatectomy and 1 post-radiation. Among patients treated with radical prostatectomy, higher PI-RADS v2 scores were significantly associated with risk of BCR (pooled HR 3.06, 95% CI 2.16-4.33; p <0.01). There was no significant heterogeneity among studies. For all studies, PI-RADS v2 score remained significantly associated with BCR (pooled HR 3.19, 95% CI 2.28-4.45; p <0.01). CONCLUSIONS: Prostate MRI findings assessed with the PI-RADS v2 classification were independently associated with risk of BCR after definitive local therapy, primarily based on data from radical prostatectomy. These findings support the prognostic significance of MRI, in addition to its role in prostate cancer diagnosis.
650    _2
$a brachyterapie $7 D001918
650    _2
$a lidé $7 D006801
650    _2
$a kalikreiny $x krev $7 D007610
650    12
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lokální recidiva nádoru $x krev $x diagnóza $x epidemiologie $x prevence a kontrola $7 D009364
650    _2
$a prognóza $7 D011379
650    _2
$a prostata $x diagnostické zobrazování $x účinky záření $x chirurgie $7 D011467
650    _2
$a prostatický specifický antigen $x krev $7 D017430
650    _2
$a prostatektomie $7 D011468
650    _2
$a nádory prostaty $x krev $x diagnóza $x epidemiologie $x terapie $7 D011471
650    _2
$a hodnocení rizik $x metody $7 D018570
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Mori, Keiichiro $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Huebner, Nicolai A $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Working Group for Diagnostic Imaging in Urology, Austrian Association of Urology, Vienna, Austria
700    1_
$a Martin, Darryl T $u Department of Urology, Yale School of Medicine, New Haven, Connecticut
700    1_
$a Sprenkle, Preston C $u Department of Urology, Yale School of Medicine, New Haven, Connecticut
700    1_
$a Weinreb, Jeffrey C $u Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut
700    1_
$a Ploussard, Guillaume $u Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France
700    1_
$a Pradere, Benjamin $u Department of Urology, Medical University of Vienna, Vienna, Austria
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Weill Cornell Medical College, New York, New York $u Department of Urology, University of Texas Southwestern, Dallas, Texas $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
700    1_
$a Leapman, Michael S $u Department of Urology, Yale School of Medicine, New Haven, Connecticut
773    0_
$w MED00003040 $t The Journal of urology $x 1527-3792 $g Roč. 206, č. 3 (2021), s. 507-516
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33904755 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026134207 $b ABA008
999    __
$a ok $b bmc $g 1714200 $s 1145546
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 206 $c 3 $d 507-516 $e 20210427 $i 1527-3792 $m The Journal of urology $n J Urol $x MED00003040
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace